HPTN Publications

An Exploration of Geographic Access to Substance Use Treatment Programs and Violence Against Women. J Interpers Violence.

Global HIV Incidence Analysis and Implications for Affordability Using Long-Acting Cabotegravir Versus Continuous and Event-Driven Oral Preexposure Prophylaxis. 2023

1. Edupuganti E, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton KE, Domin E, Lin BC, McKee K, Doria-Rose N, Regenold S, Spiegel H, Anderson M, McClosky N, Zhang L, Piwowar-Manning E, Acker, Edupuganti E, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton KE, Domin E, Lin BC, McKee K, Doria-Rose N, Regenold S, Spiegel H, Anderson M, McClosky N, Zhang L, Piwowar-Manning E, Ackerman ME, Sobieszczyk M, Pensiero M, Dye BJ, Landovitz RJ, Mayer K, Siegel M, Walsh SR, Gama L, Barouch DH, Montefiori DC, Tomaras GD . Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092). Lancet HIV. 2025, 12

Abdool Karim Q, Sibeko S, Baxter C . Preventing HIV infection in women: a global health imperative. Clin Infect Dis. 2010, 50: S122-9